These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors. Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones. Eldehna WM; Ibrahim HS; Abdel-Aziz HA; Farrag NN; Youssef MM Eur J Med Chem; 2015 Jan; 89():549-60. PubMed ID: 25462265 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives. Xue DQ; Zhang XY; Wang CJ; Ma LY; Zhu N; He P; Shao KP; Chen PJ; Gu YF; Zhang XS; Wang CF; Ji CH; Zhang QR; Liu HM Eur J Med Chem; 2014 Oct; 85():235-44. PubMed ID: 25086915 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells. Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100278. PubMed ID: 34596910 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
11. Mono- and bis-pyrazolophthalazines: Design, synthesis, cytotoxic activity, DNA/HSA binding and molecular docking studies. Hamidinasab M; Ameri A; Hekmat A; Forootanfar H; Mortezazadeh T; Bodaghifard MA; Peytam F; Esmaeili R; Foroumadi A; Sharifzadeh M; Mobinikhaledi A; Khoobi M Bioorg Med Chem; 2021 Jan; 30():115944. PubMed ID: 33352388 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, antitumor activity, and molecular docking study of 2-cyclopentyloxyanisole derivatives: mechanistic study of enzyme inhibition. El-Husseiny WM; El-Sayed MA; El-Azab AS; AlSaif NA; Alanazi MM; Abdel-Aziz AA J Enzyme Inhib Med Chem; 2020 Dec; 35(1):744-758. PubMed ID: 32183576 [TBL] [Abstract][Full Text] [Related]
14. Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives. Mohamed MF; Hassaneen HM; Elzayat EM; El-Hallouty SM; El-Manawaty M; Saleh FM; Mohamed Y; El-Zohiry D; Fahmy G; Abdelaal N; Hassanin N; Hossam N Anticancer Agents Med Chem; 2019; 19(9):1141-1149. PubMed ID: 30843494 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440 [TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors. El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers. Metwally NH; Mohamed MS; Ragb EA Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of some novel 1,2,3-triazole hybrids of myrrhanone B isolated from Commiphora mukul gum resin: Identification of potent antiproliferative leads active against prostate cancer cells (PC-3). Madasu C; Karri S; Sangaraju R; Sistla R; Uppuluri MV Eur J Med Chem; 2020 Feb; 188():111974. PubMed ID: 31883489 [TBL] [Abstract][Full Text] [Related]
19. Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers. Ghorab MM; Alsaid MS; Al-Ansary GH; Abdel-Latif GA; Abou El Ella DA Eur J Med Chem; 2016 Nov; 124():946-958. PubMed ID: 27770735 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]